Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model.
Neuropharmacology October 1, 2024 Carolyn J Stopera, Mitchell J Bartlett, Chenxi Liu et al. 9 citations
Sub-anesthetic ketamine treatment has been shown to be an effective therapy for treatment-resistant depression and chronic pain. Our group has previously shown that sub-anesthetic ketamine produces acute anti-parkinsonian, and acute anti-dyskinetic effects in preclinical models of Parkinson's disease (PD). Ketamine is a multifunctional drug and exerts effects through blockade of...
DOI: 10.1016/j.neuropharm.2024.110047 (opens in new tab)
Full text (opens in new tab)
6-hydroxydopamine
Levodopa-induced dyskinesia
Microdialysis
Naloxone
+6